Scientists Crack Nature's Secret for Better Cancer Drugs

New Delhi, India Jul 9, 2026 ALN: Scientists have uncovered how bacteria naturally manufacture multiple versions of powerful cancer drugs, solving a mystery that has puzzled researchers for decades. The discovery could help speed the development of new treatments for cancers that are still difficult to treat. This breakthrough not only enhances our understanding of bacterial biosynthesis but also opens the door to innovative drug design strategies that could significantly impact cancer therapy.

For years, scientists have hoped to harness bacterial enzymes to create new drug variants through a process known as combinatorial biosynthesis. This approach allows for the combination of different chemical building blocks to create a diverse array of compounds. However, progress has been limited because researchers did not fully understand how the enzymes coordinate their work. The complexity of these biochemical systems and the intricacies of enzyme interactions posed significant challenges for researchers in the field.

Published in Nature Communications, the new study reveals how bacterial enzymes communicate with one another to assemble a family of closely related anti-cancer compounds. That family includes Romidepsin (Istodax), an FDA-approved treatment for certain blood cancers, which has been a cornerstone in the treatment of T-cell lymphomas. By uncovering this natural "mix and match" system and reproducing its underlying principles in the laboratory, the researchers have established a new strategy for designing future cancer therapies that may be more effective and tailored to individual patient needs.

"For decades, we've known that bacteria can naturally produce multiple versions of powerful anti-cancer drugs, yet we had no idea how they achieved this," said first author Dr. Munro Passmore, Research Fellow, Department of Chemistry, University of Warwick. "This work finally cracks that code. We've identified how the different enzymes communicate and cooperate to produce these drug variants, something that has eluded researchers because the system is so elegantly economical. It's the breakthrough we needed to actually engineer these drugs ourselves." This statement underscores the long-standing challenge in drug development: understanding and replicating the efficient processes found in nature.

Tiny Molecular Connectors Reveal Nature's Drug-Making Strategy

The researchers discovered that small molecular regions known as 'docking domains' serve as connectors between the core drug-building machinery and the enzymes responsible for adding different components. These docking domains share a conserved connection point that allows them to interact with multiple enzyme partners. This flexible design explains how bacteria can create a variety of related drug molecules while still maintaining the precision needed for the compounds to remain effective. The implications of this finding are vast, potentially allowing for the rapid development of new drugs that could address unmet medical needs.

The study also sheds light on how these natural drug-producing systems evolved. According to the researchers, the newly identified compound most likely developed from a related drug-producing pathway through gene duplication and recombination over time. Understanding the evolutionary history of these pathways could provide insights into how to manipulate them for therapeutic purposes, potentially leading to the creation of drugs that are more effective or have fewer side effects.

Prof. Greg Challis, Monash Warwick Alliance Professor of Sustainable Chemistry, University of Warwick and Monash University, concludes: "This research gives us a blueprint to do what nature does, but better and faster. By reverse-engineering nature's evolutionary logic, we can now design synthetic pathways that generate new anti-cancer drug candidates with properties optimized for clinical use, such as superior potency, improved selectivity, and fewer side effects. Our immediate goal is to build an expanded library of candidates for various cancers where new treatments are urgently needed. This discovery is moving us from understanding how the systems work to building new ones." This statement highlights the potential for this research to transform the landscape of cancer treatment.

How the Discovery Could Improve Cancer Drug Development

The work focuses on a class of anti-cancer medicines known as HDAC inhibitors. These drugs block histone deacetylases, enzymes that help regulate which genes are switched on or off inside cells. Romidepsin (Istodax) is an FDA-approved HDAC inhibitor used to treat T-cell lymphomas, showcasing the clinical relevance of this research. The discovery of how bacteria synthesize related compounds could lead to the identification of new HDAC inhibitors that are more effective or have fewer side effects compared to existing therapies.

A chemically related compound called FR-901375 has been known for decades, but scientists had never identified the biological pathway bacteria use to produce it. This study finally fills in that missing piece, providing a clearer understanding of how these compounds are generated. Such knowledge is critical, as it can guide future research efforts in drug development and optimization.

Like other HDAC inhibitors in its family, FR-901375 belongs to a group of complex cyclic molecules called depsipeptides. These compounds are assembled from amino acid building blocks along with a conserved hydroxy acid pharmacophore, all connected through a combination of peptide and ester bonds. Understanding the structure and function of these molecules is key to developing new drugs that can effectively target cancer cells while minimizing harm to y cells.

Inside bacteria, these molecules are built by massive protein complexes called PKS-NRPS hybrids, which combine the activities of polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS). The new research shows that the key to this assembly process is the docking domains, which act like molecular connectors that allow one part of the production line to recognize and pass its product to the next. This mechanism is what enables combinatorial biosynthesis and allows bacteria to naturally generate multiple drug variants. The ability to harness this mechanism for synthetic biology is a promising avenue for future research.

How the Researchers Solved the Mystery

To uncover how this system works, the team combined structural biology, biochemistry, genetics, and computational modeling. Their multidisciplinary approach highlights the importance of collaboration across different scientific fields in solving complex biological questions.

• Bioinformatic searches of public databases identified the FR-901375 biosynthetic gene cluster in Pseudomonas chlororaphis subsp. piscium, with the findings confirmed by mass spectrometry analysis of extracted metabolites. This step was crucial in pinpointing the genetic basis for the biosynthesis of the compound.
• In vitro reconstitution experiments using purified protein domains demonstrated productive enzyme-enzyme interactions, verified with intact protein mass spectrometry. These experiments provided direct evidence of how the enzymes work together to produce the desired compounds.
• AlphaFold computational modeling was employed to predict protein complex structures, followed by carbene footprinting mass spectrometry to experimentally map the interaction sites. This innovative use of technology allowed the researchers to visualize and confirm the interactions at a molecular level.
• Site-directed mutagenesis experiments confirmed the importance of the predicted binding residues. By altering specific amino acids, the researchers could assess how changes impacted the production of the compounds.
• Gene deletion studies in bacterial strains showed that the docking domains are essential for the system to function in vivo. This finding underscores the critical role these connectors play in the biosynthetic process.
• Comparative analysis of biosynthetic gene clusters from multiple HDAC inhibitor-producing bacteria revealed evolutionarily conserved features shared across these natural drug-making systems. Such comparative studies can provide insights into the evolutionary pressures that shaped these pathways and may inform future engineering efforts.

This comprehensive approach not only elucidates the mechanisms of bacterial drug synthesis but also sets the stage for the development of new therapeutic strategies that could revolutionize cancer treatment. As researchers continue to explore the potential of bacterial biosynthesis, the hope is that these findings will lead to innovative drugs that can effectively combat a wide range of cancers, ultimately improving patient outcomes and survival rates.